Two isoforms of tissue transglutaminase mediate opposing cellular fates

Opposing cellular responses are typically regulated by distinct sets of genes. However, tissue transglutaminase (TGase) provides an interesting example of a single gene product that has been implicated both in affording protection against cellular insults as well as in promoting cell death. Here, we shed some light on how these conflicting activities might be manifested by demonstrating that alternative transcripts of TGase differentially affect cell viability. We show that although the full-length TGase protein affords strong protection against cell death signals, a shorter version of TGase that is truncated at the 3′ end, and thus called TGase-short (TGase-S), is cytotoxic. The apoptotic activity of TGase-S is not dependent on its transamidation activity because the mutation of a cysteine residue that is essential for catalyzing this reaction does not compromise the ability of TGase-S to induce cell death. Intriguingly, TGase-S undergoes inappropriate oligomer formation in cells before cell death, suggesting a novel mechanism for the apoptotic effects of this protein.

[1]  K. Mehta,et al.  Implications of increased tissue transglutaminase (TG2) expression in drug-resistant breast cancer (MCF-7) cells , 2006, Oncogene.

[2]  R. Graham,et al.  Mutation of a Critical Arginine in the GTP-binding Site of Transglutaminase 2 Disinhibits Intracellular Cross-linking Activity* , 2006, Journal of Biological Chemistry.

[3]  H. Yamaguchi,et al.  Tissue Transglutaminase Serves as an Inhibitor of Apoptosis by Cross-Linking Caspase 3 in Thapsigargin-Treated Cells , 2006, Molecular and Cellular Biology.

[4]  M. Chicoine,et al.  Tissue transglutaminase 2 inhibition promotes cell death and chemosensitivity in glioblastomas , 2005, Molecular Cancer Therapeutics.

[5]  L. Fésüs,et al.  Transglutaminase 2 in the balance of cell death and survival , 2005, FEBS letters.

[6]  C. Khosla,et al.  Chemistry and biology of dihydroisoxazole derivatives: selective inhibitors of human transglutaminase 2. , 2005, Chemistry & biology.

[7]  R. Cerione,et al.  Augmentation of Tissue Transglutaminase Expression and Activation by Epidermal Growth Factor Inhibit Doxorubicin-induced Apoptosis in Human Breast Cancer Cells* , 2004, Journal of Biological Chemistry.

[8]  R. Cerione,et al.  Activation of the Ras-ERK Pathway Inhibits Retinoic Acid-induced Stimulation of Tissue Transglutaminase Expression in NIH3T3 Cells* , 2003, The Journal of Biological Chemistry.

[9]  P. Thibault,et al.  Identification of differentially expressed proteins in human glioblastoma cell lines and tumors , 2003, Glia.

[10]  Soo-Youl Kim,et al.  Tissue transglutaminase-induced aggregation of α-synuclein: Implications for Lewy body formation in Parkinson's disease and dementia with Lewy bodies , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[11]  Robert M. Graham,et al.  Transglutaminases: crosslinking enzymes with pleiotropic functions , 2003, Nature Reviews Molecular Cell Biology.

[12]  Rita Casadio,et al.  Transglutaminases: nature's biological glues. , 2002, The Biochemical journal.

[13]  S. Hersch,et al.  Therapeutic Effects of Cystamine in a Murine Model of Huntington's Disease , 2002, The Journal of Neuroscience.

[14]  G. Melino,et al.  ‘Tissue’ transglutaminase ablation reduces neuronal death and prolongs survival in a mouse model of Huntington's disease , 2002, Cell Death and Differentiation.

[15]  R. Cerione,et al.  Tissue Transglutaminase Protects against Apoptosis by Modifying the Tumor Suppressor Protein p110 Rb* , 2002, The Journal of Biological Chemistry.

[16]  K. Santacruz,et al.  Injury‐induced ‘switch’ from GTP‐regulated to novel GTP‐independent isoform of tissue transglutaminase in the rat spinal cord , 2002, Journal of neurochemistry.

[17]  G. Johnson,et al.  Tissue transglutaminase differentially modulates apoptosis in a stimuli‐dependent manner , 2002, Journal of neurochemistry.

[18]  Sawsan Youssef,et al.  Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine , 2002, Nature Medicine.

[19]  K. Santacruz,et al.  Protein crosslinking, tissue transglutaminase, alternative splicing and neurodegeneration , 2002, Neurochemistry International.

[20]  R. Cerione,et al.  Effects of Tissue Transglutaminase on Retinoic Acid-induced Cellular Differentiation and Protection against Apoptosis* , 2001, The Journal of Biological Chemistry.

[21]  G. Johnson,et al.  Tissue transglutaminase is essential for neurite outgrowth in human neuroblastoma SH-SY5Y cells , 2001, Neuroscience.

[22]  C. Rodolfo,et al.  Inhibition of “Tissue” Transglutaminase Increases Cell Survival by Preventing Apoptosis* , 1999, The Journal of Biological Chemistry.

[23]  R. Ferrante,et al.  Tissue Transglutaminase Is Increased in Huntington's Disease Brain , 1999, Journal of neurochemistry.

[24]  Soo-Youl Kim,et al.  Differential Expression of Multiple Transglutaminases in Human Brain , 1999, The Journal of Biological Chemistry.

[25]  D. Price,et al.  Transglutaminase aggregates huntingtin into nonamyloidogenic polymers, and its enzymatic activity increases in Huntington's disease brain nuclei. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[26]  H. Green,et al.  Transglutaminase action imitates Huntington's disease: selective polymerization of Huntingtin containing expanded polyglutamine. , 1998, Molecular cell.

[27]  R. Powers,et al.  Transglutaminase activity is increased in Alzheimer's disease brain , 1997, Brain Research.

[28]  O. Eizenberg,et al.  Expression of GTP-dependent and GTP-independent Tissue-type Transglutaminase in Cytokine-treated Rat Brain Astrocytes* , 1997, The Journal of Biological Chemistry.

[29]  R. Cerione,et al.  Biochemical Effects of Retinoic Acid on GTP-binding Protein/Transglutaminases in HeLa Cells , 1996, The Journal of Biological Chemistry.

[30]  G. Melino,et al.  Tissue transglutaminase and apoptosis: sense and antisense transfection studies with human neuroblastoma cells , 1994, Molecular and cellular biology.

[31]  R. Gonzales,et al.  A retinoic acid-inducible mRNA from human erythroleukemia cells encodes a novel tissue transglutaminase homologue. , 1992, The Journal of biological chemistry.

[32]  M. Saraste,et al.  FEBS Lett , 2000 .